应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
CLRB Cellectar Biosciences Inc.
休市中 05-17 16:00:00 EDT
3.30
-0.03
-0.90%
盘后
3.30
+0.00
0.00%
16:00 EDT
最高
3.42
最低
3.28
成交量
63.62万
今开
3.33
昨收
3.33
日振幅
4.20%
总市值
1.18亿
流通市值
8,879万
总股本
3,585万
成交额
212.51万
换手率
2.36%
流通股本
2,691万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Cellectar Biosciences, Inc.2024财年第一财季实现净利润-21.58百万美元,同比减少151.52%
自选股智能写手 · 00:11
Cellectar Biosciences, Inc.2024财年第一财季实现净利润-21.58百万美元,同比减少151.52%
Cellectar Biosciences, Inc.盘中异动 大幅上涨5.07%报3.22美元
自选股智能写手 · 05-14
Cellectar Biosciences, Inc.盘中异动 大幅上涨5.07%报3.22美元
Cellectar Biosciences, Inc.盘中异动 急速下挫5.09%报3.08美元
自选股智能写手 · 05-11
Cellectar Biosciences, Inc.盘中异动 急速下挫5.09%报3.08美元
Cellectar Biosciences, Inc.盘中异动 快速上涨5.09%报3.51美元
自选股智能写手 · 05-03
Cellectar Biosciences, Inc.盘中异动 快速上涨5.09%报3.51美元
Cellectar Biosciences, Inc.盘中异动 急速拉升5.07%报3.25美元
自选股智能写手 · 05-01
Cellectar Biosciences, Inc.盘中异动 急速拉升5.07%报3.25美元
Cellectar Biosciences Inc 预计每股亏损 56 美分 - 财报前瞻
Reuters · 04-30
Cellectar Biosciences Inc 预计每股亏损 56 美分 - 财报前瞻
Cellectar Biosciences, Inc.盘中异动 急速上涨5.28%报3.19美元
自选股智能写手 · 04-30
Cellectar Biosciences, Inc.盘中异动 急速上涨5.28%报3.19美元
Cellectar Biosciences, Inc.盘中异动 下午盘股价大涨5.28%
自选股智能写手 · 04-23
Cellectar Biosciences, Inc.盘中异动 下午盘股价大涨5.28%
Cellectar Biosciences, Inc.盘中异动 下午盘急速下跌5.30%
自选股智能写手 · 04-19
Cellectar Biosciences, Inc.盘中异动 下午盘急速下跌5.30%
Cellectar Biosciences, Inc.盘中异动 下午盘股价大跌5.10%
自选股智能写手 · 04-16
Cellectar Biosciences, Inc.盘中异动 下午盘股价大跌5.10%
Cellectar Biosciences, Inc.盘中异动 下午盘急速下跌5.12%
自选股智能写手 · 04-13
Cellectar Biosciences, Inc.盘中异动 下午盘急速下跌5.12%
Cellectar Biosciences, Inc.盘中异动 股价大涨5.01%
自选股智能写手 · 04-12
Cellectar Biosciences, Inc.盘中异动 股价大涨5.01%
Cellectar Biosciences, Inc.盘中异动 股价大跌5.09%
自选股智能写手 · 04-11
Cellectar Biosciences, Inc.盘中异动 股价大跌5.09%
Cellectar Biosciences, Inc.盘中异动 股价大跌5.03%报3.78美元
自选股智能写手 · 04-05
Cellectar Biosciences, Inc.盘中异动 股价大跌5.03%报3.78美元
Cellectar Biosciences, Inc.盘中异动 股价大涨7.02%
自选股智能写手 · 03-28
Cellectar Biosciences, Inc.盘中异动 股价大涨7.02%
Cellectar Biosciences, Inc.2023财年实现净利润-37.98百万美元,同比减少32.80%
自选股智能写手 · 03-28
Cellectar Biosciences, Inc.2023财年实现净利润-37.98百万美元,同比减少32.80%
Cellectar Biosciences, Inc.盘中异动 股价大跌5.33%
自选股智能写手 · 03-27
Cellectar Biosciences, Inc.盘中异动 股价大跌5.33%
Cellectar 生物科学公司公布截至 12 月的季度业绩 - 收益摘要
Reuters · 03-27
Cellectar 生物科学公司公布截至 12 月的季度业绩 - 收益摘要
Cellectar Biosciences Inc 预计每股亏损 57 美分 - 财报前瞻
Reuters · 03-25
Cellectar Biosciences Inc 预计每股亏损 57 美分 - 财报前瞻
Cellectar Biosciences, Inc.盘中异动 股价大涨5.17%
自选股智能写手 · 03-23
Cellectar Biosciences, Inc.盘中异动 股价大涨5.17%
暂无数据
公司概况
公司名称:
Cellectar Biosciences Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Cellectar Biosciences, Inc.以前名为Novelos Therapeutics, Inc.于1996年6月成立于特拉华州。2014年2月11日,公司更名为现在的名字。它是一家生物制药公司,开发用于治疗肿瘤成像化合物。该公司的癌症靶向技术允许选择性递送的多种剂对癌症细胞,包括癌症干细胞。该公司目前正在开发三种专利的候选产品:I-124-CLR1404 是一种小分子,广谱,肿瘤的靶向性的正电子发射断层扫描(PET)显像剂,该公司认为其必须在范围广泛的癌症肿瘤和转移的选择性检测的第一种可能。I-131-CLR1404是一种小分子,广谱,癌靶向分子放射治疗的直接和选择性地提供细胞毒性(细胞杀伤)辐射到癌细胞和癌干细胞。CLR1502是一种临床前,小分子,肿瘤靶向,非放射性的光学成像术中肿瘤边缘照明和非侵入性的肿瘤成像剂。
发行价格:
--
{"stockData":{"symbol":"CLRB","market":"US","secType":"STK","nameCN":"Cellectar Biosciences Inc.","latestPrice":3.3,"timestamp":1715976000000,"preClose":3.33,"halted":0,"volume":636156,"hourTrading":{"tag":"盘后","latestPrice":3.3,"preClose":3.3,"latestTime":"16:00 EDT","volume":362,"amount":1194.6,"timestamp":1715976001313},"delay":0,"floatShares":26905000,"shares":35848924,"eps":-3.054512,"marketStatus":"休市中","marketStatusCode":7,"change":-0.03,"latestTime":"05-17 16:00:00 EDT","open":3.33,"high":3.42,"low":3.28,"amount":2125131.537254,"amplitude":0.042042,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.054512,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1716192000000},"adr":0,"adjPreClose":3.33,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":3.3401,"preClose":3.33,"latestTime":"09:15 EDT","volume":3397,"amount":11360.8398368,"timestamp":1715951708710},"postHourTrading":{"tag":"盘后","latestPrice":3.3,"preClose":3.3,"latestTime":"16:00 EDT","volume":362,"amount":1194.6,"timestamp":1715976001313},"volumeRatio":0.7920028324255085},"requestUrl":"/m/hq/s/CLRB/tweets","defaultTab":"tweets","newsList":[{"id":"2436198049","title":"Cellectar Biosciences, Inc.2024财年第一财季实现净利润-21.58百万美元,同比减少151.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436198049","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436198049?lang=zh_cn&edition=full","pubTime":"2024-05-20 00:11","pubTimestamp":1716135103,"startTime":"0","endTime":"0","summary":"3月31日,Cellectar Biosciences, Inc.公布财报,公告显示公司2024财年第一财季净利润为-21.58百万美元,同比减少151.52%;其中营业收入为0.00美元,每股基本收益为-0.74美元。从资产负债表来看,Cellectar Biosciences, Inc.总负债16.74百万美元,其中短期债务73994.00美元,资产负债比为2.57,流动比率为2.55。机构评级:截至2024年3月31日,当前有4家机构对Cellectar Biosciences, Inc.目标价做出预测,其中目标均价为15.25美元,其中最低目标价为7.00美元,最高目标价为28.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405200011568b1863e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405200011568b1863e1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435951120","title":"Cellectar Biosciences, Inc.盘中异动 大幅上涨5.07%报3.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435951120","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435951120?lang=zh_cn&edition=full","pubTime":"2024-05-14 21:48","pubTimestamp":1715694484,"startTime":"0","endTime":"0","summary":"北京时间2024年05月14日21时48分,Cellectar Biosciences, Inc.股票出现异动,股价快速拉升5.07%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.10%。其相关个股中,Nls Pharmaceutics Ltd C/Wts 02/02/2026、Generation Bio Co.、Seastar Medical Holding Corp C/Wts 28/10/2027 涨幅较大,Allarity Therapeutics, Inc.、Transcode Therapeutics, Inc.、诺瓦瓦克斯医药较为活跃,换手率分别为59.46%、10.71%、10.49%,振幅较大的相关个股有Tc Biopharm Plc C/Wts 10/02/2028 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Fennec Pharmaceuticals Inc.,振幅分别为65.81%、33.57%、27.54%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405142148047a59d946&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405142148047a59d946&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434886969","title":"Cellectar Biosciences, Inc.盘中异动 急速下挫5.09%报3.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2434886969","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2434886969?lang=zh_cn&edition=full","pubTime":"2024-05-11 00:04","pubTimestamp":1715357041,"startTime":"0","endTime":"0","summary":"北京时间2024年05月11日00时04分,Cellectar Biosciences, Inc.股票出现异动,股价大幅跳水5.09%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.09%。其相关个股中,诺瓦瓦克斯医药、Clene Inc C/Wts 30/12/2025 、Iteos Therapeutics, Inc.涨幅较大,Transcode Therapeutics, Inc.、诺瓦瓦克斯医药、Allarity Therapeutics, Inc.较为活跃,换手率分别为187.38%、92.10%、50.10%,振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Estrella Immunopharma Inc C/Wts 29/09/2028、Cardio Diagnostics Holdings Inc.,振幅分别为77.01%、70.00%、53.60%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405110004017a594420&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405110004017a594420&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432757908","title":"Cellectar Biosciences, Inc.盘中异动 快速上涨5.09%报3.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432757908","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432757908?lang=zh_cn&edition=full","pubTime":"2024-05-03 21:47","pubTimestamp":1714744028,"startTime":"0","endTime":"0","summary":"北京时间2024年05月03日21时47分,Cellectar Biosciences, Inc.股票出现波动,股价快速上涨5.09%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.46%。其相关个股中,Protagenic Therapeutics Inc C/Wts 29/04/2026 、Vaxxinity, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大,Allarity Therapeutics, Inc.、Vaxxinity, Inc.、Jaguar Health, Inc.较为活跃,换手率分别为103.30%、26.77%、15.93%,振幅较大的相关个股有Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Effector Therapeutics Inc C/Wts 31/12/2025 、Revolution Medicines Inc C/Wts 17/12/2026 ,振幅分别为54.50%、30.65%、26.55%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240503214708861ead81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240503214708861ead81&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432503035","title":"Cellectar Biosciences, Inc.盘中异动 急速拉升5.07%报3.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432503035","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432503035?lang=zh_cn&edition=full","pubTime":"2024-05-01 22:20","pubTimestamp":1714573254,"startTime":"0","endTime":"0","summary":"北京时间2024年05月01日22时20分,Cellectar Biosciences, Inc.股票出现异动,股价急速上涨5.07%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.27%。其相关个股中,Cytomx Therapeutics, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Palisade Bio, Inc.涨幅较大,Palisade Bio, Inc.、Cytomx Therapeutics, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃,换手率分别为1165.67%、118.20%、33.15%,振幅较大的相关个股有Cytomx Therapeutics, Inc.、Cassava Sciences Inc C/Wts 15/11/2024、Palisade Bio, Inc.,振幅分别为188.34%、48.20%、32.84%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050122205487e852f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050122205487e852f0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431608321","title":"Cellectar Biosciences Inc 预计每股亏损 56 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2431608321","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2431608321?lang=zh_cn&edition=full","pubTime":"2024-04-30 22:03","pubTimestamp":1714485790,"startTime":"0","endTime":"0","summary":" * Cellectar Biosciences Inc 预计在5月2日公布截至2024年3月31日的业绩时,季度收入将没有变化(预计)。* * LSEG分析师对Cellectar Biosciences Inc的平均预期是每股亏损56美分。* 华尔街对 Cellectar Biosciences Inc 的 12 个月目标价中位数为 12.50 美元,高于其上一次收盘价 3.10 美元。4月30日 - 以前季度业绩。除非另有说明,所有数字均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431897403","title":"Cellectar Biosciences, Inc.盘中异动 急速上涨5.28%报3.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431897403","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431897403?lang=zh_cn&edition=full","pubTime":"2024-04-30 00:06","pubTimestamp":1714406806,"startTime":"0","endTime":"0","summary":"北京时间2024年04月30日00时06分,Cellectar Biosciences, Inc.股票出现异动,股价大幅拉升5.28%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.76%。其相关个股中,Calidi Biotherapeutics, Inc.、Nkgen Biotech Inc C/Wts 31/05/2028、Zura Bio Limited C/Wts 涨幅较大,Zyversa Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Annovis Bio, Inc.较为活跃,换手率分别为961.17%、50.49%、40.99%,振幅较大的相关个股有Calidi Biotherapeutics, Inc.、Annovis Bio, Inc.、Nkgen Biotech Inc C/Wts 31/05/2028,振幅分别为98.32%、79.12%、75.06%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240430000646792505b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240430000646792505b0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429870977","title":"Cellectar Biosciences, Inc.盘中异动 下午盘股价大涨5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429870977","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429870977?lang=zh_cn&edition=full","pubTime":"2024-04-23 01:52","pubTimestamp":1713808362,"startTime":"0","endTime":"0","summary":"北京时间2024年04月23日01时52分,Cellectar Biosciences, Inc.股票出现异动,股价快速上涨5.28%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为1.97%。其相关个股中,Moolec Science Sa C/Wts 、Nkgen Biotech Inc C/Wts 31/05/2028、Moolec Science Sa涨幅较大,Moolec Science Sa、Phio Pharmaceuticals Corp.、Nkgen Biotech, Inc.较为活跃,换手率分别为197.11%、104.45%、86.60%,振幅较大的相关个股有Moolec Science Sa C/Wts 、Moolec Science Sa、Phio Pharmaceuticals Corp.,振幅分别为252.97%、82.14%、68.75%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042301524279226240&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042301524279226240&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428510281","title":"Cellectar Biosciences, Inc.盘中异动 下午盘急速下跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428510281","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428510281?lang=zh_cn&edition=full","pubTime":"2024-04-19 01:32","pubTimestamp":1713461538,"startTime":"0","endTime":"0","summary":"北京时间2024年04月19日01时32分,Cellectar Biosciences, Inc.股票出现异动,股价快速下挫5.30%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.62%。其相关个股中,Bio-Path Holdings, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大,Bio-Path Holdings, Inc.、Benitec Biopharma Inc.、Soligenix, Inc.较为活跃,换手率分别为9862.97%、106.97%、43.19%,振幅较大的相关个股有Bio-Path Holdings, Inc.、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Aileron Therapeutics, Inc.,振幅分别为86.72%、73.93%、68.47%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240419013218792196c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240419013218792196c1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427388003","title":"Cellectar Biosciences, Inc.盘中异动 下午盘股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427388003","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427388003?lang=zh_cn&edition=full","pubTime":"2024-04-16 03:11","pubTimestamp":1713208302,"startTime":"0","endTime":"0","summary":"北京时间2024年04月16日03时11分,Cellectar Biosciences, Inc.股票出现波动,股价大幅跳水5.10%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.56%。其相关个股中,Cingulate Inc C/Wts 10/12/2026 、安皮奥制药、Longeveron Inc.涨幅较大,Longeveron Inc.、Soligenix, Inc.、Allarity Therapeutics, Inc.较为活跃,换手率分别为1579.11%、1244.68%、879.83%,振幅较大的相关个股有安皮奥制药、Soligenix, Inc.、Cassava Sciences Inc C/Wts 15/11/2024,振幅分别为273.33%、117.12%、80.04%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160311427920a702&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160311427920a702&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427561751","title":"Cellectar Biosciences, Inc.盘中异动 下午盘急速下跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427561751","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427561751?lang=zh_cn&edition=full","pubTime":"2024-04-13 02:51","pubTimestamp":1712947919,"startTime":"0","endTime":"0","summary":"北京时间2024年04月13日02时51分,Cellectar Biosciences, Inc.股票出现异动,股价快速下跌5.12%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为1.52%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗,iopofosine是一种小分子PDC,旨在提供碘-131直接靶向传输到癌细胞,同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041302515987e80040&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041302515987e80040&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426627202","title":"Cellectar Biosciences, Inc.盘中异动 股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426627202","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426627202?lang=zh_cn&edition=full","pubTime":"2024-04-12 00:07","pubTimestamp":1712851623,"startTime":"0","endTime":"0","summary":"北京时间2024年04月12日00时07分,Cellectar Biosciences, Inc.股票出现异动,股价急速拉升5.01%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.84%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗,iopofosine是一种小分子PDC,旨在提供碘-131直接靶向传输到癌细胞,同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412000703791ff4f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412000703791ff4f1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426448778","title":"Cellectar Biosciences, Inc.盘中异动 股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426448778","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426448778?lang=zh_cn&edition=full","pubTime":"2024-04-11 01:14","pubTimestamp":1712769289,"startTime":"0","endTime":"0","summary":"北京时间2024年04月11日01时14分,Cellectar Biosciences, Inc.股票出现波动,股价大幅下跌5.09%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为1.28%。其相关个股中,Adial Pharmaceuticals, Inc、Jaguar Health, Inc.、Orgenesis Inc.涨幅较大,Adial Pharmaceuticals, Inc、Silo Pharma, Inc.、Jaguar Health, Inc.较为活跃,换手率分别为1948.44%、76.79%、53.39%,振幅较大的相关个股有Adial Pharmaceuticals, Inc、Orgenesis Inc.、Nutriband Inc C/Wts ,振幅分别为87.61%、74.23%、52.44%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110114507a51ed9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110114507a51ed9a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425341921","title":"Cellectar Biosciences, Inc.盘中异动 股价大跌5.03%报3.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425341921","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425341921?lang=zh_cn&edition=full","pubTime":"2024-04-05 02:42","pubTimestamp":1712256136,"startTime":"0","endTime":"0","summary":"北京时间2024年04月05日02时42分,Cellectar Biosciences, Inc.股票出现异动,股价急速下跌5.03%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.73%。其相关个股中,Candel Therapeutics, Inc.、Tc Biopharm Plc C/Wts 10/02/2028 、Tc Biopharm Plc涨幅较大,Tc Biopharm Plc、Candel Therapeutics, Inc.、Effector Therapeutics, Inc.较为活跃,换手率分别为3497.50%、317.89%、220.37%,振幅较大的相关个股有Candel Therapeutics, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Tc Biopharm Plc,振幅分别为142.86%、133.46%、111.54%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405024217791ecf5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405024217791ecf5f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422419414","title":"Cellectar Biosciences, Inc.盘中异动 股价大涨7.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422419414","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422419414?lang=zh_cn&edition=full","pubTime":"2024-03-28 21:32","pubTimestamp":1711632730,"startTime":"0","endTime":"0","summary":"北京时间2024年03月28日21时32分,Cellectar Biosciences, Inc.股票出现波动,股价急速拉升7.02%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.13%。其相关个股中,Avalo Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Nutriband Inc C/Wts 涨幅较大,Avalo Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Ibio, Inc.较为活跃,换手率分别为359.94%、289.00%、261.08%,振幅较大的相关个股有Avalo Therapeutics, Inc.、Nutriband Inc C/Wts 、Psyence Biomedical Ltd C/Wts 25/01/2029,振幅分别为52.63%、41.04%、31.00%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403282132108b6dfc2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403282132108b6dfc2a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422920760","title":"Cellectar Biosciences, Inc.2023财年实现净利润-37.98百万美元,同比减少32.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422920760","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422920760?lang=zh_cn&edition=full","pubTime":"2024-03-28 06:13","pubTimestamp":1711577595,"startTime":"0","endTime":"0","summary":"12月31日,Cellectar Biosciences, Inc.公布财报,公告显示公司2023财年净利润为-37.98百万美元,同比减少32.80%;其中营业收入为0.00美元,每股基本收益为-3.11美元。从资产负债表来看,Cellectar Biosciences, Inc.总负债13.43百万美元,其中短期债务58979.00美元,资产负债比为0.90,流动比率为0.81。机构评级:截至2023年12月31日,当前有4家机构对Cellectar Biosciences, Inc.目标价做出预测,其中目标均价为14.75美元,其中最低目标价为7.00美元,最高目标价为28.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280613218b6b1a72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280613218b6b1a72&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422199741","title":"Cellectar Biosciences, Inc.盘中异动 股价大跌5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422199741","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422199741?lang=zh_cn&edition=full","pubTime":"2024-03-27 21:32","pubTimestamp":1711546336,"startTime":"0","endTime":"0","summary":"北京时间2024年03月27日21时32分,Cellectar Biosciences, Inc.股票出现波动,股价大幅跳水5.33%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.34%。其相关个股中,Ibio, Inc.、Lixte Biotechnology Holdings, Inc.、Lixte Biotechnology Holdings Inc C/Wts 30/11/2025 涨幅较大,Ibio, Inc.、Lixte Biotechnology Holdings, Inc.、Hoth Therapeutics, Inc.较为活跃,换手率分别为877.64%、392.13%、48.75%,振幅较大的相关个股有Ibio, Inc.、Lixte Biotechnology Holdings, Inc.、Annexon, Inc.,振幅分别为32.17%、19.73%、15.19%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272132177a4f874b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272132177a4f874b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422499293","title":"Cellectar 生物科学公司公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2422499293","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422499293?lang=zh_cn&edition=full","pubTime":"2024-03-27 21:31","pubTimestamp":1711546273,"startTime":"0","endTime":"0","summary":" * Cellectar Biosciences Inc 报告,截至12月底的季度调整后每股亏损61美分,低于去年同期的每股收益-55美分。四位分析师对该季度的平均预期是每股亏损 57 美分。华尔街的预期在每股-78美分到-39美分之间。* Cellectar Biosciences Inc 报告的季度每股收益为亏损 61 美分。* 公司当季亏损 745 万美元。* Cellectar Biosciences Inc 的股价本季度上涨了 39.0%。* 医药同行的平均一致建议是 \"买入\"。华尔街对 Cellectar Biosciences Inc 的 12 个月目标价中位数为 12.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422751148","title":"Cellectar Biosciences Inc 预计每股亏损 57 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2422751148","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422751148?lang=zh_cn&edition=full","pubTime":"2024-03-25 20:41","pubTimestamp":1711370503,"startTime":"0","endTime":"0","summary":" * Cellectar Biosciences Inc 将于3月27日公布截至2023年12月31日的财报,预计该公司的季度收入将保持不变。* * LSEG分析师对Cellectar Biosciences Inc的平均预期是每股亏损57美分。* 华尔街对 Cellectar Biosciences Inc 的 12 个月目标价中位数为 12.00 美元,高于其最新收盘价 4.05 美元。3月25日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421318828","title":"Cellectar Biosciences, Inc.盘中异动 股价大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421318828","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421318828?lang=zh_cn&edition=full","pubTime":"2024-03-23 01:29","pubTimestamp":1711128557,"startTime":"0","endTime":"0","summary":"北京时间2024年03月23日01时29分,Cellectar Biosciences, Inc.股票出现波动,股价急速拉升5.17%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.09%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗,iopofosine是一种小分子PDC,旨在提供碘-131直接靶向传输到癌细胞,同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403230129177a4e8e84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403230129177a4e8e84&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cellectar.com","stockEarnings":[{"period":"1week","weight":0.0749},{"period":"1month","weight":0.028},{"period":"3month","weight":-0.0421},{"period":"6month","weight":0.5865},{"period":"1year","weight":1.2148},{"period":"ytd","weight":0.1913}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cellectar Biosciences, Inc.以前名为Novelos Therapeutics, Inc.于1996年6月成立于特拉华州。2014年2月11日,公司更名为现在的名字。它是一家生物制药公司,开发用于治疗肿瘤成像化合物。该公司的癌症靶向技术允许选择性递送的多种剂对癌症细胞,包括癌症干细胞。该公司目前正在开发三种专利的候选产品:I-124-CLR1404 是一种小分子,广谱,肿瘤的靶向性的正电子发射断层扫描(PET)显像剂,该公司认为其必须在范围广泛的癌症肿瘤和转移的选择性检测的第一种可能。I-131-CLR1404是一种小分子,广谱,癌靶向分子放射治疗的直接和选择性地提供细胞毒性(细胞杀伤)辐射到癌细胞和癌干细胞。CLR1502是一种临床前,小分子,肿瘤靶向,非放射性的光学成像术中肿瘤边缘照明和非侵入性的肿瘤成像剂。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.027916},{"month":2,"riseRate":0.6,"avgChangeRate":0.012926},{"month":3,"riseRate":0.5,"avgChangeRate":-0.02847},{"month":4,"riseRate":0.2,"avgChangeRate":-0.095326},{"month":5,"riseRate":0.4,"avgChangeRate":0.054087},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.058603},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.066667},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.019682},{"month":9,"riseRate":0.4,"avgChangeRate":-0.041969},{"month":10,"riseRate":0.1,"avgChangeRate":-0.147573},{"month":11,"riseRate":0.4,"avgChangeRate":-0.05683},{"month":12,"riseRate":0.4,"avgChangeRate":0.02288}],"exchange":"NASDAQ","name":"Cellectar Biosciences Inc.","nameEN":"Cellectar Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cellectar Biosciences Inc.(CLRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cellectar Biosciences Inc.(CLRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cellectar Biosciences Inc.,CLRB,Cellectar Biosciences Inc.股票,Cellectar Biosciences Inc.股票老虎,Cellectar Biosciences Inc.股票老虎国际,Cellectar Biosciences Inc.行情,Cellectar Biosciences Inc.股票行情,Cellectar Biosciences Inc.股价,Cellectar Biosciences Inc.股市,Cellectar Biosciences Inc.股票价格,Cellectar Biosciences Inc.股票交易,Cellectar Biosciences Inc.股票购买,Cellectar Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cellectar Biosciences Inc.(CLRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cellectar Biosciences Inc.(CLRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}